Pharmaceutical company Merck has announced that its molnupiravir pill-based COVID-19 treatment “significantly” reduced the rates of hospital...
Pharmaceutical company Merck has announced that its molnupiravir pill-based COVID-19 treatment “significantly” reduced the rates of hospitalization and death among patients during its Phase 3 MOVe-OUT trial. The benefits were observed among participants who had mild to moderate COVID-19, but who weren’t hospitalized at the time they started taking the oral treatment. Molnupiravir is a pill that patients who have … Continue reading
from SlashGear https://ift.tt/3Beds9T
via IFTTT
from SlashGear https://ift.tt/3Beds9T
via IFTTT
COMMENTS